Openbookopenbook
Equity
ANL
+0.0 · +0.00%
USD · NASDAQ

Adlai Nortye Ltd. American Depositary Shares(ANL) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk66Medium-High
75%Data
Thin -125% profit margin · Revenue growing 178% YoY
Structurally Challenged
Market Cap:882.25M
ⓘ
Reward Rating
34
Low
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
66
Medium-High
Risk Assessment
7 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ANL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ANL, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $28.60.

What is Adlai Nortye Ltd. American Depositary Shares?

, a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products.

ANL · Verdict

Limited reward · elevated risk

ANL has limited near-term tailwinds — balance sheet and growth weigh on the model output.

Based on 88% data coverage

ANL · Verdict

What’s working & what to watch

Watchouts 4

  • Balance sheet6/100

    Current ratio 0.65

  • Growth16/100

    Earnings -15.5% CAGR

  • Cash flow29/100

    -675% free-cash-flow margin

  • Profitability32/100

    -711% net margin · -20% ROE

Model-based scoring. For information only — not financial advice.

What is Adlai Nortye Ltd. American Depositary Shares?

, a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 882.25M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

DBVTSmall Cap / 881M market cap
DBV Technologies
Compare
TBPHSmall Cap / 881M market cap
Theravance Biopharma Inc
Compare
SGPSmall Cap / 876M market cap
SpyGlass Pharma, Inc.
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap882.25M
P/E RatioN/A
Dividend YieldN/A
Beta1.119
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.